Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379399 | 0.76 | GAA (0.37) | GAAL3MBTL1 | |
| SCHEMBL1072805 | 0.76 | GAA (0.37) | GAAL3MBTL1 | |
| Tempol SCHEMBL23234 | 0.74 | GAA (0.37) | GAAL3MBTL1 | |
| SCHEMBL7636853 | 0.72 | GAA (0.31) | GAAL3MBTL1 | |
| SCHEMBL14165214 | 0.72 | GAA (0.58) | GAAL3MBTL1 | |
| SCHEMBL1814713 | 0.72 | GAA (1.00) | GAAL3MBTL1 | |
| SCHEMBL377189 | 0.70 | GAA (0.30) | GAAL3MBTL1 | |
| SCHEMBL16245364 | 0.70 | GAA (0.30) | GAAL3MBTL1 | |
| SCHEMBL475361 | 0.70 | APLNR (0.38) | GAAL3MBTL1 | |
| SCHEMBL2992832 | 0.70 | ADORA3 (0.36) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264495-A1 | ORAL SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION OF INDAPAMIDE, PRODUCTION AND USE THEREOF | STANDARD CHEM. & PHARM. CO., LTD. (TW) | 2009-10-22 | — | — | US | claimed |
| US-7473795-B2 | Blends of quinone alkide and nitroxyl compounds as polymerization inhibitors | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2009-01-06 | — | — | US | claimed |
| US-7259192-B2 | Molecular weight reduction of polysaccharides by electron beams | RHODIA, INC. (US) | 2007-08-21 | — | — | US | claimed |
| EP-1438277-B1 | RECYCLE OF NITROXYL-CONTAINING STREAMS AT LOW TEMPERATURE | UNIROYAL CHEM CO INC (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060182803-A1 | Oral sustained-release pharmaceutical composition of indapamide, production and use thereof | STANDARD CHEM. & PHARM. CO., LTD. | 2006-08-17 | — | — | US | claimed |
| US-20060155140-A1 | Blends of quinone alkide and nitroxyl compounds as polymerization inhibitors | UNIROYAL CHEMICAL COMPANY, INC A CORPORATION OF THE STATE OF DELAWARE | 2006-07-13 | — | — | US | claimed |
| US-7045647-B2 | Blends of quinone alkide and nitroxyl compounds and polymerization inhibitors | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2006-05-16 | — | — | US | claimed |
| EP-1551882-A4 | MOLECULAR WEIGHT REDUCTION OF POLYSACCHARIDES BY ELECTRON BEAMS | RHODIA (US) | 2005-12-14 | — | — | EP | claimed |
| JP-2005530897-A | — | — | 2005-10-13 | — | — | JP | claimed |
| EP-1551882-A2 | MOLECULAR WEIGHT REDUCTION OF POLYSACCHARIDES BY ELECTRON BEAMS | Rhodia, Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| WO-2004000885-A2 | MOLECULAR WEIGHT REDUCTION OF POLYSACCHARIDES BY ELECTRON BEAMS | RHODIA, INC. (US) | 2003-12-31 | — | — | WO | claimed |
| EP-1332196-A1 | BLENDS OF QUINONE ALKIDE AND NITROXYL COMPOUNDS AS POLYMERIZATION INHIBITORS | Uniroyal Chemical Company, Inc. (US) | 2003-08-06 | — | — | EP | claimed |
| US-20020123658-A1 | Recycle of nitroxyl-containing streams at low temperature | CROMPTON CORPORATION | 2002-09-05 | — | — | US | claimed |
| EP-1235885-A1 | COMPOSITION AND METHOD FOR INHIBITING POLYMERIZATION AND POLYMER GROWTH | Uniroyal Chemical Company, Inc. (US) | 2002-09-04 | — | — | EP | claimed |
| US-20020048820-A1 | Method for measuring concentration of stable free radical compound | HAKUTO CO., LTD. | 2002-04-25 | — | — | US | claimed |
| WO-2002033026-A1 | BLENDS OF QUINONE ALKIDE AND NITROXYL COMPOUNDS AS POLYMERIZATION INHIBITORS | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2002-04-25 | — | — | WO | claimed |
| WO-2001040404-A1 | COMPOSITION AND METHOD FOR INHIBITING POLYMERIZATION AND POLYMER GROWTH | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| EP-0738824-B1 | Delayed borate crosslinked fracturing fluid having increased temperature range | SOFITECH NV (BE) | 2000-11-29 | — | — | EP | claimed |
| US-5407657-A | Containing a metal chelate and a free radical nitroxide | IMARX THERAPEUTICS, INC. | 1995-04-18 | — | — | US | claimed |
| US-4786503-A | Dosage form comprising parallel lamine | ALZA CORPORATION (US) | 1988-11-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155140-A1 | Blends of quinone alkide and nitroxyl compounds as polymerization inhibitors | SQOR, NQO1, NQO2 | GAA 2221/4885L3MBTL1 2553/4885 |
| US-20020123658-A1 | Recycle of nitroxyl-containing streams at low temperature | NQO2, NOS2, NOS1 | GAA 2720/4885L3MBTL1 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.